Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Investigational Site Number 1560001, Beijing

Investigational Site Number 1560038, Beijing

Investigational Site Number 1560005, Shenyang

Investigational Site Number 1560028, Dalian

Investigational Site Number 1560010, Dalian

Investigational Site Number 1560020, Changchun

Investigational Site Number 1560012, Changchun

Investigational Site Number 1560046, Harbin

Investigational Site Number 1560003, Shanghai

Investigational Site Number 1560004, Shanghai

Investigational Site Number 1560014, Nanjing

Investigational Site Number 1560007, Zhenjiang

Investigational Site Number 1560021, Changzhou

Investigational Site Number 1560023, Wuxi

Investigational Site Number 1560017, Suzhou

Investigational Site Number 1560026, Huai'an

Investigational Site Number 1560009, Hefei

Investigational Site Number 1560006, Jinan

Investigational Site Number 1560018, Pingxiang

Investigational Site Number 1560030, Fuzhou

Investigational Site Number 1560024, Chongqing

Investigational Site Number 1560011, Changsha

Investigational Site Number 1560016, Zhuzhou

Investigational Site Number 1560022, Wuhan

Investigational Site Number 1560042, Zhengzhou

Investigational Site Number 1560032, Guangzhou

Investigational Site Number 1560027, Guangzhou

Investigational Site Number 1560039, Baotou

Investigational Site Number 1560040, Baotou

Investigational Site Number 1560035, Cangzhou

Investigational Site Number 1560036, Dalian

Investigational Site Number 1560041, Hangzhou

Investigational Site Number 1560033, Kunming

Investigational Site Number 1560034, Luoyang

Investigational Site Number 1560013, Shanghai

Investigational Site Number 1560019, Shijiazhuang

Investigational Site Number 1560015, Xiangtan

Investigational Site Number 1560037, Zhongshan

Investigational Site Number 1560025, Hohhot

Investigational Site Number 1560043, Yuncheng